Clinical trial · Observational
Skeletal Events of Hormonal Treatment and Radiotherapy in Patient With Breast Cacer
Lymphedema and Skeletal Events in Older Patients Receiving Adjuvant Hormonal and Radiotherarpy in Breast Cancer
NCT04792840CI-TRIAL-00050619unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
study of lymphedema and skeletal events in breast cacer patient receiving adjuvant hormonal therapy and radiothearpy
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Femara Pill | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (2)
- measure
- Skeletal events caused by hermonal treatment
- timeFrame
- basline
- description
- Hermonal treatment in breast Cancer patients may caused osteoporosis that can be measured by dexascan
- measure
- Radiotherapy and arm edema
- timeFrame
- Baseline
- description
- Radiothearpy on axilla my increase arm edema in breast cancer patients measuredvby arm circumference in centimeters
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 40 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * Postmenopausal patients with positive diagnosis of stage 1-3 breast cancer and planned AI (anastrazole, letrozole) adjuvant treatment will be included in the study. * Patients without known osteoporosis will included in the study, and before AI treatment began. * Conventional RT course must be completed (50 Gy/25 fractions, 2 Gy/fraction, 5 days/week). * Patients continue to receive adjuvant hormonal treatment (aromatase inhibitors) or adjuvant target therapy (trastuzumab) while monitoring late toxicities Exclusion Criteria: * Male patients * Metastatic disease at presentation * No definitive surgery * Carcinoma in situ or other rare tumors of the breast as phyllodes tumors.
References
Publications (0)
Data not yet available
No reference posted for this study.